Study of Alfimeprase's Ability to Dissolve Blood Clots in the Leg and Help Prevent the Need for Surgery
Phase 3, Multicenter, Multi-National, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Alfimeprase in Subjects With Acute Peripheral Arterial Occlusion (NAPA-3)
Sponsor: ARCA Biopharma, Inc.
Terminated
Based upon preliminary safety and efficacy results from a similar study.
Other terminated trials from ARCA Biopharma, Inc.
More terminations from ARCA Biopharma, Inc.
Other Arterial Occlusive Diseases trials with similar outcome
Listed as NCT00338585, this PHASE3 trial focuses on Arterial Occlusive Diseases and remains terminated or withdrawn. Sponsored by ARCA Biopharma, Inc., it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Apr 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- ARCA Biopharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .